| ORIGINAL ARTICLE |
|
| Ahead of Print |
|
|
Long-term outcomes of EUS-guided lauromacrogol ablation for the treatment of pancreatic cystic neoplasms: 5 years of experience
Chen Du, Ningli Chai, Enqiang Linghu, Huikai Li, Xiuxue Feng, Bo Ning, Xiangdong Wang, Ping Tang
Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China
Correspondence Address:
Enqiang Linghu,
Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, No. 28 of Fuxing Road, Haidian District, Beijing
China
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/EUS-D-20-00231 PMID: 33473042
|
|
|
Background and Objectives: We initially reported EUS-guided lauromacrogol ablation (EUS-LA) to treat pancreatic cystic neoplasms (PCNs); however, its long-term effectiveness remains unknown. This study was performed to further determine the effectiveness of EUS-LA in a larger population with a long-term follow-up based on 5 years of experience with EUS-LA. Materials and Methods: From April 2015 to April 2020, 279 patients suspected of having PCNs were prospectively enrolled, and seventy patients underwent EUS-guided ablation using lauromacrogol alone. Fifty-five patients underwent follow-up, 35 of whom had a follow-up duration of at least 12 months. The effectiveness of ablation was determined based on volume changes. Results: Among the fifty female and twenty male patients with an overall mean age of 50.3 years, cysts were located in the head/neck of the pancreas in 37 patients (52.9%) and in the body/tail of the pancreas in 33 patients (47.1%). The adverse events rate was 3.6% (3/84), with 14 patients undergoing a second ablation. Among the 55 patients who underwent follow-up, the median cystic volume sharply decreased from 11,494.0 mm3 to 523.6 mm3 (P < 0.001), and the mean diameter decreased from 32.0 mm to 11.0 mm (P < 0.001). Postoperative imaging showed complete resolution (CR) in 26 patients (47.3%) and partial resolution (PR) in 15 (27.3%) patients. CR was observed in 18 (51.4%), and PR was observed in 9 (25.7%) patients among the 35 patients followed for at least 12 months. Conclusions: EUS-LA was effective and safe for the treatment of PCNs with stable effectiveness based on at least 12 months of follow-up.
|
|
|
|
|
|
|
Search Pubmed for